Media ReleasesLBT Innovations

View All LBT Innovations News

LBT Innovations - Direct Sale of APAS Independence in United States

Adelaide, Australia, 3 May 2022: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence, is pleased to announce the sale of an APAS® Independence with Urine analysis module to Albany Medical Center, NY.

Key Points:

* Albany Medical Center purchase APAS® Independence with Urine analysis module
* Direct sale completed by Clever Culture Systems, LBT’s wholly owned subsidiary
* Sale completed after successful 6-week evaluation-to-buy completed by the laboratory  

LBT’s wholly owned subsidiary, Clever Culture Systems (CCS) has executed a binding sale agreement for an APAS® Independence supplied to New York state-based, Albany Medical Center. The sale follows a successful evaluation-to-buy completed by the laboratory, where they assessed the performance of the APAS® Independence with Urine analysis module over a 6-week period. The APAS® Independence met all of the target performance criteria and was positively received by staff in the laboratory.

The laboratory is part of the Albany Medical Center health system, a not-for-profit health system with 1,520 hospital beds across 4 hospitals in north-eastern New York. The Division of Laboratory Medicine provides a full suite of diagnostic services to the hospital and collectively conducts over 7 million tests every year. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.